STAT5A (Ab-694) Antibody

What is the biological significance of STAT5A phosphorylation at tyrosine 694?

STAT5A is one of two STAT5 isoforms (STAT5A and STAT5B) that function as cytoplasmic signal transducers and transcription factors. The phosphorylation of tyrosine 694 (Y694) is critical for STAT5A activation and subsequent biological function. When phosphorylated at this residue, STAT5A can:

• Form homodimers or heterodimers with STAT5B

• Translocate to the nucleus

• Bind to GAS (Gamma-Activated Sequence) elements

• Activate transcription of target genes

This phosphorylation is essential for STAT5A's roles in mediating cellular responses to cytokines, growth factors, and oncogenic signals . Functionally, phosphorylated STAT5A regulates critical processes including immune cell development, proliferation, and survival.

How do STAT5A and STAT5B differ functionally despite their high sequence homology?

STAT5A (794 amino acids) and STAT5B (786 amino acids) share 93% homology at the amino acid level and are encoded by separate genes on human chromosome 17 (bands q11-1 to q22) . Despite this similarity, they exhibit important functional differences:

What activates STAT5A phosphorylation at Y694 in different cellular contexts?

Multiple stimuli can induce STAT5A phosphorylation at Y694 across different cell types:

Some leukemic cell types show constitutive STAT5 activation in the absence of cytokine stimulation, suggesting its role in oncogenesis . The specific pattern of STAT5A vs. STAT5B activation appears to be both stimulus-dependent and cell type-specific .

What are the optimal experimental conditions for phospho-STAT5A (Y694) antibody in different applications?

Researchers should optimize conditions based on their specific application:

Western Blotting:

• Recommended dilution: 1:500-1:1000

• Expected molecular weight: 90-92 kDa

• Positive controls: A431 cells treated with EGF, Daudi cells treated with IFN-α

• Blocking: 5% BSA in TBST recommended for phospho-specific antibodies

• Detection: HRP-conjugated secondary antibodies with ECL detection systems

Immunohistochemistry:

• Recommended dilution: 1:50-1:100

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Blocking: 5-10% normal serum from secondary antibody host species

• Visualization: DAB or fluorescent secondary antibodies

Flow Cytometry:

• Fixation: 2% formaldehyde (paraformaldehyde)

• Permeabilization: 100% ice-cold methanol

• Staining: Include appropriate surface markers before fixation for cell identification

Immunofluorescence:

• Fixation: Paraformaldehyde (4%) for adherent cells

• Permeabilization: 0.1-0.5% Triton X-100 or 100% methanol

• Dilution: 1:100-1:500 depending on cell type

• Counterstaining: DAPI for nuclear visualization

How can I validate the specificity of phospho-STAT5A (Y694) antibody in my experimental system?

Proper validation ensures reliable experimental results. Implementation of multiple approaches is recommended:

• Peptide competition assay: Pre-incubate antibody with the immunizing phosphopeptide to block specific binding, as demonstrated in immunohistochemical analysis of breast carcinoma tissue .

• Positive and negative controls:

  • Stimulated cells: A431 cells + EGF, Daudi cells + IFN-α

  • Unstimulated counterparts: Same cell lines without stimulation

  • Phosphatase treatment: Lambda phosphatase to remove phosphorylation

• Genetic approaches:

  • STAT5A knockout or knockdown cells

  • STAT5A Y694F mutants (non-phosphorylatable)

  • Comparison with STAT5B-deficient cells to assess cross-reactivity

• Pharmacological inhibition:

  • JAK inhibitors for cytokine-induced phosphorylation

  • Tyrosine kinase inhibitors (e.g., imatinib for BCR-ABL-induced phosphorylation)

• Signal localization assessment:

  • Nuclear translocation upon stimulation

  • Cytoplasmic versus nuclear fractionation analysis

A combination of these approaches provides comprehensive validation of antibody specificity and experimental reliability.

What controls are essential when using phospho-STAT5A (Y694) antibody in western blotting?

Robust western blot experiments require appropriate controls:

For quantitative analysis, always include a standard curve using serial dilutions of a positive control lysate to ensure measurements fall within the linear range of detection.

How do phospho-STAT5A detection methods differ between primary immune cells and cell lines?

Working with primary immune cells presents unique challenges compared to established cell lines:

For primary immune cells, flow cytometry is often preferred over western blotting due to the ability to identify specific cell populations using surface markers. The protocol should include:

• Surface marker staining with appropriate antibodies

• Fixation with 2% formaldehyde

• Permeabilization with 100% ice-cold methanol

• Intracellular staining with phospho-STAT5A (Y694) antibody

This approach allows assessment of phospho-STAT5A levels in specific immune cell subsets even when limited cell numbers are available.

How does BCR-ABL-induced STAT5A phosphorylation differ from cytokine-induced phosphorylation?

BCR-ABL oncogenic signaling activates STAT5 through mechanisms distinct from normal cytokine signaling:

These differences may contribute to the oncogenic properties of BCR-ABL and offer potential therapeutic targets. Notably, "RNAi targeting STAT5B but not STAT5A sensitizes human BCR-ABL-positive cell lines to imatinib-treatment" , suggesting isoform-specific approaches could enhance current therapies for BCR-ABL-positive leukemias.

What are the implications of detecting phospho-STAT5A in subcellular compartments other than the nucleus?

While conventional understanding places activated STAT5A primarily in the nucleus, detection in other cellular compartments has important implications:

Membrane localization:

• BCR-ABL tyrosine kinase activity induces STAT5A-eGFP translocation to the cell membrane and co-localization with the IL-3 receptor

• May indicate non-canonical signaling roles or sequestration preventing normal nuclear function

• Could provide insight into pathological mechanisms in malignant transformation

Cytoplasmic retention:

• Reduced nuclear accumulation observed in BCR-ABL expressing cells compared to IL-3 stimulation

• May reflect altered dimerization patterns or additional regulatory phosphorylation events

• Could represent a mechanism for signal attenuation or prolongation

Quantitative assessment:

• The nuclear-to-cytoplasmic ratio of phospho-STAT5A can be quantified using fractionation approaches

• Subcellular distribution may serve as a biomarker for specific disease states or drug responses

• Changes in distribution patterns may precede alterations in total phosphorylation levels

These observations challenge the simple linear model of STAT5 signaling and suggest more complex regulation involving specific subcellular localization patterns that may be functionally significant in both normal and pathological contexts.

What are common issues in phospho-STAT5A (Y694) detection and their solutions?

For flow cytometry applications specifically:

• Ensure adequate permeabilization with 100% methanol after formaldehyde fixation

• Use bright fluorophores for detection of phospho-epitopes

• Include appropriate FMO (fluorescence minus one) controls

• Perform titration experiments to determine optimal antibody concentration

How should I interpret differential STAT5A and STAT5B phosphorylation patterns?

Interpreting differential phosphorylation patterns requires consideration of several factors:

• Paralog preference versus specificity:

  • Most genes show "paralog preference" rather than absolute specificity

  • The majority of STAT5-sensitive genes are affected by both STAT5A and STAT5B, but to different degrees

  • Only a small subset of genes appear truly isoform-specific

• Cell type-specific patterns:

  • IFN-α activates both STAT5A and STAT5B in B cells but only STAT5A in HeLa cells

  • Consider the relative expression levels of each isoform in your cell type

• Stimulus-dependent differences:

  • BCR-ABL induces different patterns of STAT5A/B activation compared to cytokines

  • Time-course experiments may reveal dynamic differences in activation patterns

• Dimerization dynamics:

  • Consider the balance between STAT5A:STAT5A homodimers, STAT5B:STAT5B homodimers, and STAT5A:STAT5B heterodimers

  • BCR-ABL is less efficient at inducing heterodimers compared to IL-3

• Subcellular localization:

  • Nuclear versus cytoplasmic distribution can differ between isoforms and stimuli

  • Membrane localization may indicate non-canonical signaling roles

When interpreting these patterns, it's critical to consider the biological context and functional outcomes rather than focusing solely on phosphorylation status.

How do I quantitatively assess STAT5A phosphorylation levels across experimental conditions?

Quantitative assessment requires rigorous methodology and appropriate normalization:

Western Blot Analysis:

• Use a dilution series of positive control to establish a standard curve

• Ensure signal falls within linear range of detection

• Normalize phospho-STAT5A signal to total STAT5A from the same sample

• Use digital imaging systems rather than film for more accurate quantification

• Apply appropriate statistical analyses for multiple experimental replicates

Flow Cytometry:

• Calculate the fold change in mean fluorescence intensity (MFI) between stimulated and unstimulated samples

• Use median rather than mean values if distributions are skewed

• Include appropriate isotype controls and FMO controls

• Report both percentage of positive cells and MFI values

• Consider ratio of phospho-STAT5A to total STAT5A when possible

Immunofluorescence Microscopy:

• Measure nuclear-to-cytoplasmic ratio of phospho-STAT5A signal

• Analyze multiple cells (>100) per condition for statistical robustness

• Use automated image analysis software to reduce subjective bias

• Include internal controls in each image field when possible

Subcellular Fractionation:

• Verify clean separation of nuclear and cytoplasmic fractions

• Normalize to compartment-specific markers (e.g., HDAC1 for nucleus, GAPDH for cytoplasm)

• Calculate both absolute phospho-STAT5A levels and phospho-to-total STAT5A ratios in each fraction

What new insights have emerged about STAT5A phosphorylation beyond Y694?

While Y694 phosphorylation is the canonical activation mark for STAT5A, recent research has revealed additional layers of complexity:

• Additional phosphorylation sites:

  • Y682 phosphorylation detected in BCR-ABL expressing cells by mass spectrometry

  • Serine phosphorylation sites that may modulate activity or protein-protein interactions

• Post-translational modifications beyond phosphorylation:

  • ISGylation of STAT5A may regulate protein stability or function

  • Other potential modifications including acetylation, methylation, and sumoylation

• Structural insights:

  • Crystal structures of phosphorylated STAT proteins have revealed conformational changes beyond simple dimerization

  • These structural details may inform more specific therapeutic approaches

• Non-canonical functions:

  • Membrane localization suggesting potential non-transcriptional roles

  • Possible functions in mitochondria and other subcellular compartments

These emerging insights suggest that STAT5A regulation and function are more complex than previously appreciated, with important implications for both basic research and therapeutic targeting.

What are the therapeutic implications of STAT5A/B isoform-specific inhibition?

Research on differential roles of STAT5 isoforms suggests promising therapeutic approaches:

• Selective targeting potential:

  • "RNAi targeting STAT5B but not STAT5A sensitizes human BCR-ABL-positive cell lines to imatinib-treatment"

  • Suggests STAT5B-specific inhibition could enhance current therapies while potentially reducing side effects

• Dose-dependent approaches:

  • "Partial inhibition of STAT5 expression and/or activity may be sufficient to have desired effects on immune cell function"

  • Lower doses of pan-STAT5 inhibitors might achieve therapeutic effects with reduced toxicity

• Safety considerations:

  • "Targeting of STAT5A may be safer (though perhaps less robust) than targeting of STAT5B"

  • Differential targeting could enable precision medicine approaches

• Context-specific strategies:

  • BCR-ABL+ leukemias show particular dependence on STAT5B for BCL-XL expression and proliferation

  • Other disease contexts might have different isoform dependencies

• Combination therapies:

  • STAT5 inhibition could be combined with current therapies targeting upstream activators

  • Overcoming resistance mechanisms through multiple pathway targeting

These findings provide a molecular rationale for exploiting STAT5 paralog redundancy and preference in clinical settings, potentially improving therapeutic windows for STAT5-directed interventions.

How does tyrosine phosphorylation of both STAT5A and STAT5B influence their cooperative functions in vivo?

Recent research using CRISPR/Cas9 gene editing to generate tyrosine-to-phenylalanine mutants (Y694F in STAT5A and Y699F in STAT5B) has provided critical insights:

• Requirement for dual phosphorylation:

  • Phosphorylation of both STAT5A (Y694) and STAT5B (Y699) appears necessary for proper immune cell development and function

  • Mutants show more severe defects in T and NK cells than corresponding knockout models

• Complex functional interplay:

  • The two isoforms exhibit both redundant and unique functions

  • Some biological processes have different thresholds of total STAT5 activity requirement

• Dimerization dynamics:

  • Phosphorylation is essential for the formation of both homodimers and heterodimers

  • The specific ratio of different dimer configurations may determine certain biological outcomes

• Transcriptional programs:

  • Different genes show varying sensitivity to total STAT5 dose

  • Some genes require both isoforms to be phosphorylated for optimal expression

This research highlights the importance of studying STAT5A and STAT5B phosphorylation not just in isolation but as part of an integrated signaling system with complex cooperative functions in vivo.